Giacomo Forti

Publications by Year

Research Areas

Inflammatory Bowel Disease, Microscopic Colitis, Diverticular Disease and Complications, Gastrointestinal disorders and treatments, Colorectal Cancer Screening and Detection

Most-Cited Works

• → Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study(2010)484 cited
• Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.(2004)
• → Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease - a double-blind, randomised, placebo-controlled study(2013)153 cited
• → Development and Validation of an Endoscopic Classification of Diverticular Disease of the Colon: The DICA Classification(2014)81 cited
• → Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study(2015)50 cited
• → Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients(2021)47 cited
• → Prognostic performance of the ‘DICA’ endoscopic classification and the ‘CODA’ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study(2021)33 cited
• → Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers(2017)30 cited
• → Functional Renal Alterations in Chronic Liver Diseases(1980)28 cited
• → Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study(2022)27 cited